Microfluidic Droplet Platform for Ultra-High Throughput Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug combination screening technologies are limited by high costs, slow throughput, and the inability to efficiently test vast numbers of combinations due to reliance on automated liquid handling, which restricts the exploration of novel therapeutic approaches.
Innovation Solution
A microfluidic droplet platform that combines drug libraries with live cell libraries, using unique identifiers for each drug and cell, allowing for the formation of merged sets and the identification of effective drug combinations based on criteria such as cell viability and biomarker presence, enabling ultra-high throughput screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If automated liquid handling is used for drug combination screening, then the screening process can be automated, but the throughput is limited and the cost is high
Solution Approach 1:
The patent segments the drug combination screening process into individual droplet units, where each droplet contains a unique combination of drugs and cell identifiers. This segmentation enables parallel processing of thousands of combinations simultaneously, dramatically increasing throughput while maintaining automation. The droplet-based microfluidic system divides the screening task into discrete, independently processable units.
Solution Approach 2:
The patent transitions from traditional two-dimensional well plate screening to a multi-dimensional droplet system where combinations are encoded in the spatial and compositional dimensions of microfluidic droplets. This dimensional change allows for ultra-high throughput screening by packing and processing numerous droplet combinations in parallel within a small volume.
2Extent of automation
If automated liquid handling is used for drug combination screening, then the process can be performed systematically, but the cost of consumables and reagents is significant
Solution Approach 1:
The patent segments reagents and drugs into minute droplet volumes, typically nanoliters or picoliters per droplet. This segmentation reduces the total reagent consumption by orders of magnitude compared to traditional well plate formats, while maintaining systematic evaluation capability through automated droplet generation and processing.
Solution Approach 2:
The patent changes the volume parameter of reagent consumption from microliter/well scale to nanoliter/picoliter droplet scale. This parameter change dramatically reduces the total amount of expensive reagents and consumables required while preserving the systematic and reproducible nature of automated screening.
3Productivity
If traditional screening methods are used, then the process is manageable, but the time required to screen combinations is excessive (2.5 years for 5,000 combinations)
Solution Approach 1:
The patent implements continuous droplet generation, merging, and screening processes in a microfluidic flow system. This continuous operation eliminates the batch processing delays inherent in traditional methods, allowing thousands of drug combinations to be screened in parallel without interruption, reducing screening time from years to days or hours.
Solution Approach 2:
The patent performs preliminary encoding of drug and cell identifiers into droplets before the actual screening interaction. This preliminary action includes pre-mixing drugs with unique molecular barcodes or fluorescent labels, and pre-preparing cell-laden droplets with identification markers, enabling rapid identification and analysis of screening results without time-consuming post-processing.
Data Source
AI summary
A system includes a plurality of drug libraries, at least one comprising multiple droplets of multiple drugs, each drug associated with a corresponding unique drug identifier in the system, and a live cell library comprising multiple live cells or live cell lines, each live cell associated with a corresponding unique cell or cell line identifier in the system. A plurality of junctions combining drug droplets from the drug libraries and a live cell from the live cell library. At least one of said drug libraries produces a random stream of heterogenous drug droplets, the drug droplets corresponding to drugs in said drug libraries.